Emotions may be described as subjective, conscious
experiences characterized by psychophysiological expressions, mental
states, and biological reactions. Several tests such as cognitive
bias test and leaned helplessness models have been developed to
understand feelings of optimism and pessimism in animals. Cognitive
biases have been shown in wide range of species, including rats,
dogs, cats, sheep, and chicks.
Depression in animals can be due to change in
routine or change in emotions. Some animals can get depressed when
left alone for long hours. Animals can also suffer from depression
due to chemical imbalance, which can be treated with medication.
Different animals have different reactions to depression. This can be
spotted by looking out for ordinary behavior i.e. when an active
animal becomes listless and a calm animal seems anxious. Animals in
the zoo are subjected to live in artificial, stressful, and boring
conditions. Detached from their natural habitats and social
structures, they are kept in small, restrictive environments that
deprive them of mental and physical stimulation and in turn causes
depression.
Request Sample of Animal Depression Medication
Market:
https://www.coherentmarketinsights.com/insight/request-sample/90
Treatment alternatives for animal
depression to boost growth of the animal depression medication market
Treatment of animal depression varies according to
cause of condition. Blood tests, x-rays, and a physical examination
by a veterinarian can help with diagnosis. If the animal has chemical
imbalance, then the veterinarian may prescribe anti-depressants or
anxiety medication.
Paroxetine is an antidepressant used to treat
major depressive disorders, social anxiety disorder, and panic
disorder. The current standard of treatment of depression involves
use of selective serotonin reuptake inhibitors (SSRIs). Depression
can be triggered due to lack of serotonin, and SSRIs essentially
maintain higher levels of serotonin in the brain
to address the issue. It can take up to two months for a drug to be
effective in treating depression. Most dogs suffering from such
disorders can make a full recovery in six to twelve months after
being administered SSRIs. The U.S. Food and Drug Administration has
approved only one antidepressant, Clomicalm (clomipramine) for
treatment of anxiety in dogs, which would fuel growth of the animal
depression medication market.
Increasing pet adoption and growing pet
humanization trend driving growth of animal depression medication
market in Asia Pacific and Latin America
North America is a major region for animal
depression medication market. As per 2015 Pet Secure estimates, the
U.S. accounted for the highest dog population of 69,929,000. Animal
depression medication market in Asia is growing on account of
increasing awareness among the populace regarding animal illness,
increasing number of pets, and improving veterinary medical
facilities. According to the Pet Asia Fair in 2016, pet adoption in
Asia Pacific and Latin America regions is increasing rapidly
resulting in increase in demand for nutritional and medicinal
products in order to address their growing health concerns.
Increasing spending on animal care to
boost growth of the animal depression medication market
Increasing number of pet animals is a major factor
fueling growth of the animal depression medication market. According
to 2016 estimates released by Pet Secure, over half of the population
in the U.S. owns a cat or a dog. This is mainly attributed to
increasing consumer awareness regarding the various social,
emotional, and physical benefits associated with pet ownership.
Therefore, with increasing number of pets, there is an increasing
spending on pet animals, further fueled by pet humanization trend.
According to 2016 estimates of Pet Secure, the U.S. population spends
over US$ 50 billion per annum on their pets. This is projected to
fuel growth of the animal depression medications market in the near
future. Other factors include awareness about animal illness, better
medical facilities, use of latest technology in diagnosis, and
increased spending capabilities on animal treatment.
Request for a table of content :
https://www.coherentmarketinsights.com/ongoing-insight/toc/90
Key players involved in the animal
depression medication market
Major players in the global animal depression
medication market include Torrent Pharmaceuticals Limited, Elite
Pharma Private Limited, Biomax Laboratories, Intas Pharmaceuticals
Limited, Cipla Limited, and Eli Lilly and Company. These companies
provide drugs that are used to treat depression in animals.
ABOUT US:
Coherent Market Insights is a
prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations
related to emerging market trends, technologies, and potential
absolute dollar opportunity
No comments:
Post a Comment